Erasca, Inc.
ERAS
Rang în acțiuni
#3613
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Preț acțiune
$13.45
Ultima sincronizare: 2026-10-16
Capitalizare de piață
$4.70B
Schimbare (1 zi)
-9.58%
Schimbare (1 an)
455.58%
Țară
US
Tranzacționează Erasca, Inc. (ERAS)
Categorie
Healthcare
EPS pentru Erasca, Inc. (ERAS)
EPS la data de June 2026 TTM: $-0.95
Conform celor mai recente rapoarte financiare și prețului acțiunilor Erasca, Inc., EPS-ul actual al companiei (TTM) este $-0.95. La sfârșitul anului 2023, compania avea un EPS de $-0.83 o scădere comparativ cu EPS-ului din 2022, care a fost de $-1.99.
Istoricul EPS pentru Erasca, Inc. din 2019 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| 2026 (TTM) | $-0.95 | 37.68% |
| 2024 | $-0.69 | -16.87% |
| 2023 | $-0.83 | -58.29% |
| 2022 | $-1.99 | 93.20% |
| 2021 | $-1.03 | 21.18% |
| 2020 | $-0.85 | 750.00% |
| 2019 | $-0.10 | 0.00% |
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | -1,923.16% |
US
|
|
| $-7.98 | 740.00% |
US
|
|
| $-5.29 | 456.84% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -3,020.00% |
NL
|
